CORBUS PHARMACEUTICALS HOLDI
CRBPNASDAQ🏆 #4052 by market capEarnings Nov 10US Equity
$4.27—
Last available close · quote unavailableTrack CRBP
Get earnings, price moves & breaking news on Telegram
24h—
7d▲ 3.3%
14d▼ 1.4%
30d▼ 35.4%
ytd▼ 47.4%
1y▼ 74.7%
🏦Market Cap
$82M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $3.87 – $17.75
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 19.3M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-5.25
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.3%
CORBUS PHARMACEUTICALS HOLDI
CRBPFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$85M▲ +75.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$64M▲ +54.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
13.3M▲ +9.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$27M▲ +$13M YoY
StockOtter · stockotter.spaceAbout CORBUS PHARMACEUTICALS HOLDI
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.